Doing so would change the legal protection parameters for rebates between drug manufacturers, insurers, and pharmacy benefit managers. Ranking Member Wyden assailed the industry for what he deemed a “grotesque” practice of increasing the price of medicines. In opposition to Dr. Holtz-Eakin’s testimony, both Chairman Grassley and Ranking Member Wyden offered several ways they believed drug pricing could be improved. It remains important that those in the Senate continue to work on policies like this that benefit patients and not add onerous access restrictions. Medicare patients and those with chronic illnesses have the most to gain from the new HHS proposed rule.

Source: Forbes February 05, 2019 20:37 UTC